Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 26, 2026.

Sign in

Olema Pharmaceuticals, Inc.

OLMA Nasdaq Pharmaceutical Preparations Financials FY2019–FY2025

Add to portfolio Download report

Last close Β· Oct 23, 2026

$6.41

8.7%

What Olema Pharmaceuticals, Inc. does

OLMA Β· Pharmaceutical Preparations

From its latest annual report

No business description yet.

Filing details

Legal name
Olema Pharmaceuticals, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 16, 2026
Accession Β· CIK
0001193125-26-107169 Β· 0001750284

Earnings calendar Β· Olema Pharmaceuticals, Inc.

Every quarter, companies publish how much they sold and earned. These are the days Olema Pharmaceuticals, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

November 9, 2026

Monday Β· in 14 days

Time
Time not announced
Covers
Period ended Sep 30, 2026
Expected EPS
βˆ’$0.60
Source
Earnings calendar
See who else reports that week β†’
Date Results for Time Source
Aug 10, 2026 Q2 '26 After the market closes 8-K β†—
May 12, 2026 Q1 '26 Before the market opens 8-K β†—
Jan 12, 2026 Q4 '25 After the market closes 8-K β†—
Nov 10, 2025 Q3 '25 Before the market opens 8-K β†—
Aug 11, 2025 Q2 '25 After the market closes 8-K β†—
May 13, 2025 Q1 '25 After the market closes 8-K β†—
Mar 18, 2025 Q4 '24 After the market closes 8-K β†—
Nov 12, 2024 Q3 '24 After the market closes 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Olema Pharmaceuticals, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

1 to watch

Olema Pharmaceuticals, Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$162M

No. It lost money last year.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$670M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$2.13 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Olema Pharmaceuticals, Inc. lost $162M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Revenue

Margins, % of revenue

Gross Operating Net FCF

Net income and earnings per share

KIRA Β· Olema Pharmaceuticals, Inc. lost $162M in fiscal 2025.

Loss periods are shown in red.

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Net income

Net income

Diluted EPS

Diluted EPS

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

Dividends, buybacks and share count

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

Insider trades

KIRA Β· In the last 12 months, insiders sold $24.7M of shares on the open market and bought none.

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$24.7M

6 insiders

Of sales under plans

0%

$0.0M

DateInsiderTradeSharesPriceValueFiling
Jul 24, 2026 Cyrus HarmonDirector Sold 12,500 $11.71 $0.1M Form 4
Jul 23, 2026 Cyrus HarmonDirector Sold 12,500 $11.58 $0.1M Form 4
Mar 4, 2026 Shawnte MitchellChief Legal Officer Sold 25,000 $24.25 $0.6M Form 4
Mar 3, 2026 Shawnte MitchellChief Legal Officer Sold 15,000 $23.01 $0.3M Form 4
Jan 20, 2026 Cyrus HarmonDirector Sold 10,000 $26.88 $0.3M Form 4
Jan 15, 2026 Shane William Charles KovacsCH. Operating & Financial Off. Sold 100,000 $28.73 $2.9M Form 4
Jan 14, 2026 David C. MylesCH. Discov. & Non-Clin Dev Off Sold 50,000 $28.87 $1.4M Form 4
Jan 14, 2026 Cyrus HarmonDirector Sold 3,489 $29.12 $0.1M Form 4
Jan 13, 2026 David C. MylesCH. Discov. & Non-Clin Dev Off Sold 50,000 $27.60 $1.4M Form 4
Jan 13, 2026 Shane William Charles KovacsCH. Operating & Financial Off. Sold 3,822 $28.01 $0.1M Form 4
Jan 12, 2026 David C. MylesCH. Discov. & Non-Clin Dev Off Sold 10,000 $28.34 $0.3M Form 4
Dec 23, 2025 Naseem ZojwallaChief Medical Officer Sold 99,509 $27.66 $2.8M Form 4
Dec 22, 2025 Cyrus HarmonDirector Sold 2,881 $28.53 $0.1M Form 4
Dec 22, 2025 Naseem ZojwallaChief Medical Officer Sold 100,000 $28.04 $2.8M Form 4
Dec 19, 2025 Ian T ClarkDirector Sold 264,800 $29.73 $7.9M Form 4
Dec 19, 2025 Naseem ZojwallaChief Medical Officer Sold 70,000 $28.20 $2.0M Form 4
Dec 19, 2025 David C. MylesCH. Discov. & Non-Clin Dev Off Sold 51,000 $30.46 $1.6M Form 4

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Olema Pharmaceuticals, Inc. can carry it.

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $287M$204M$262M$434M$505M
Current ratio 32.2x12.6x12.3x10.5x10.0x
Quick ratio 32.2x12.6x12.3x10.5x10.0x
Total assets $296M$216M$277M$451M$533M
Total liabilities $11.4M$18.1M$23.1M$42.0M$54.9M
Shareholders' equity $285M$198M$254M$409M$479M
Net debt (βˆ’ = net cash) β€”β€”β€”β€”β€”

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

TestFY19FY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” β€” βœ• βœ• βœ“ βœ“ βœ•
Cash from operations exceeds net income βœ“ βœ“ βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” β€” β€” β€” β€”
Current ratio rose β€” β€” βœ• βœ• βœ• βœ• βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” β€” β€” β€” β€” β€”
F-score β€” / 3β€” / 4β€” / 6β€” / 6β€” / 6β€” / 6β€” / 6
Accruals ratio β€”βˆ’0.7%βˆ’6.4%βˆ’8.9%βˆ’5.2%βˆ’6.9%βˆ’3.2%
Altman Z'' β€”83.1629.7410.8211.2210.738.96

All figures

Every number, year by year.

7 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Download CSV
Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Research and development $3.9M $13.7M $51.1M $82.3M $86.1M $125M $158M
Operating income βˆ’$4.3M βˆ’$21.5M βˆ’$71.5M βˆ’$107M βˆ’$105M βˆ’$142M βˆ’$179M
Interest expense β€” $0.7M β€” β€” β€” β€” β€”
Pretax income β€” β€” β€” β€” β€” βˆ’$129M βˆ’$162M
Income tax β€” β€” β€” $0.0M $0.0M $0.0M $0.0M
Net income βˆ’$4.3M βˆ’$22.1M βˆ’$71.1M βˆ’$105M βˆ’$96.7M βˆ’$129M βˆ’$162M
Net income to common βˆ’$4.3M βˆ’$24.0M βˆ’$71.1M β€” β€” β€” β€”
Diluted EPS βˆ’$1.66 βˆ’$3.42 βˆ’$1.80 βˆ’$2.62 βˆ’$2.14 βˆ’$2.20 βˆ’$1.87
Diluted shares 0.00B 0.01B 0.04B 0.04B 0.05B 0.06B 0.09B
Cash flow
Cash from operations βˆ’$3.1M βˆ’$19.9M βˆ’$50.7M βˆ’$82.1M βˆ’$83.7M βˆ’$104M βˆ’$147M
Capital expenditure β€” $0.1M $1.6M $0.4M β€” $0.2M β€”
Free cash flow β€” βˆ’$19.9M βˆ’$52.3M βˆ’$82.4M β€” βˆ’$105M β€”
Depreciation and amortization $0.0M $0.0M $0.2M $0.4M $0.4M $0.4M $0.5M
Stock-based compensation β€” $3.1M $15.9M $18.8M $17.3M $22.6M $17.6M
Balance sheet
Cash and short-term investments $0.1M $339M $287M $204M $262M $434M $505M
Current assets β€” $342M $291M $209M $267M $438M $515M
Current liabilities β€” $4.6M $9.0M $16.5M $21.6M $41.8M $51.8M
Property and equipment, net β€” $0.1M $1.5M $1.5M $1.0M $0.7M $0.3M
Total assets β€” $343M $296M $216M $277M $451M $533M
Total liabilities β€” $4.6M $11.4M $18.1M $23.1M $42.0M $54.9M
Shareholders' equity βˆ’$10.6M $338M $285M $198M $254M $409M $479M
Returns
Return on capital employed β€” βˆ’6.4% βˆ’24.9% βˆ’53.7% βˆ’41.1% βˆ’34.8% βˆ’37.1%
Return on equity β€” βˆ’13.5% βˆ’22.8% βˆ’43.5% βˆ’42.8% βˆ’39.1% βˆ’36.6%
Return on assets β€” βˆ’6.5% βˆ’22.3% βˆ’41.0% βˆ’39.2% βˆ’35.6% βˆ’33.0%
Return on tangible equity β€” βˆ’7.1% βˆ’25.0% βˆ’53.0% βˆ’38.1% βˆ’31.7% βˆ’33.9%
Growth
Share count change β€” 170.8% 462.9% 1.2% 13.1% 29.8% 48.1%
Financial health
Interest coverage β€” βˆ’33.0x β€” β€” β€” β€” β€”
Current ratio β€” 74.6x 32.2x 12.6x 12.3x 10.5x 10.0x
Quick ratio β€” 74.6x 32.2x 12.6x 12.3x 10.5x 10.0x
Quality scores
Altman Z'' β€” 83.2 29.7 10.8 11.2 10.7 9.0
Accruals ratio β€” βˆ’0.7% βˆ’6.4% βˆ’8.9% βˆ’5.2% βˆ’6.9% βˆ’3.2%

Source: SEC EDGAR XBRL filings (CIK 0001750284). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open